Business Context and Reporting Period
This Form 6-K, dated February 6, 2004, reports the Annual Report 2003 for Novartis AG, a Swiss-based global pharmaceutical and consumer health company. The reporting period covers the fiscal year ended December 31, 2003. Novartis reported record results, solidifying its position as the fifth-largest pharmaceutical company globally. The company operates through two primary divisions: Pharmaceuticals and Consumer Health (which includes Sandoz generics, OTC, Animal Health, Medical Nutrition, Infant & Baby, and CIBA Vision).
Key Financial Metrics
| Metric | 2003 (USD) | 2002 (USD) | Change |
|---|---|---|---|
| Sales | $24.9 billion | $20.9 billion | +19% |
| Operating Income | $5.9 billion | $5.1 billion | +16% |
| Net Income | $5.0 billion | $4.7 billion | +6% |
| Earnings Per Share (Basic) | $2.03 | $1.88 | +8% |
| Free Cash Flow | $3.6 billion | $3.0 billion | +23% |
| Operating Cash Flow | $6.7 billion | $5.2 billion | +27% |
| Return on Sales | 23.7% | 24.4% | -0.7 pp |
| Return on Average Equity | 17.1% | 17.7% | -0.6 pp |
| Debt/Equity Ratio | 0.20:1 | 0.20:1 | 0% |
| Current Ratio | 2.4:1 | 2.5:1 | -0.1 |
| Dividend Per Share (CHF) | 1.00 | 0.95 | +5% |
Divisional Performance: Pharmaceuticals sales grew 18% to $16.0 billion, driven by Cardiovascular and Oncology franchises. Consumer Health sales grew 24% to $8.8 billion, heavily influenced by a 60% surge in Sandoz generics sales.
Material Changes vs. Prior Period
- Revenue Growth: Group sales increased 19% in USD (11% in local currencies). Growth was driven by volume expansion (+8%), acquisitions (+2%), and a positive currency effect (+8%) due to a weaker US dollar.
- Profitability: Operating income rose 16% to a record $5.9 billion. Net income increased 6% to $5.0 billion. The operating margin decreased slightly from 24.4% to 23.7% due to increased R&D investments and general administration costs.
- R&D Investment: Group R&D spending increased 32% to $3.8 billion (15.1% of sales), reflecting significant investment in the new Cambridge, Massachusetts research center and milestone payments for in-licensed compounds.
- Acquisitions: Novartis acquired 51% of Idenix Pharmaceuticals Inc. (infectious diseases) and the commercial rights for Lucentis (ophthalmics) outside North America. The acquisition of Lek (Slovenia) in 2002 continued to drive Sandoz growth.
- Divestitures: The Food & Beverage business was divested in late 2002; 2003 results reflect ongoing operations only.
Guidance, Outlook, and Risks
Management Commentary: CEO Daniel Vasella highlighted the company's focus on sustainable growth and innovation. The company expects to maintain capital expenditure at approximately 5.3% of sales in 2004, funded by internally generated resources. A dividend increase of 5% to CHF 1.00 per share was proposed.
Pipeline and Outlook: The development pipeline includes 79 projects in clinical development or registration, with 34 in late-stage development. Key areas of focus include diabetes, hypertension, cancer, osteoporosis, and transplantation. The company anticipates continued growth in the Cardiovascular and Oncology franchises.
Risks and Contingencies:
- Regulatory and Pricing Pressure: Increasing pressure from governments and payors to reduce pharmaceutical prices and restrict prescribing levels.
- Patent Expirations: Exposure to generic competition, though management notes a strong patent position for the next five years.
- Legal and Environmental: Ongoing litigation regarding product liability (e.g., PPA, SMON) and environmental remediation costs. The company has set aside $179 million for environmental liabilities.
- Compliance: Commitment to full compliance with the US Sarbanes-Oxley Act, including Section 404.
Key Facts for Investor Verification
- Record Net Income: Verify the $5.0 billion net income figure, noting the impact of a $200 million loss from associated companies (primarily Roche Holding AG) which offset higher operating income.
- R&D Spend: Confirm the 32% increase in R&D expenses and the specific allocation to the new US research facility and in-licensing deals.
- Sandoz Growth: Review the 60% sales growth in the Sandoz generics unit, driven by the Lek acquisition and successful US launches of AmoxC and loratadine.
- Dividend Proposal: Note the proposed dividend of CHF 1.00 per share, representing a 39% payout ratio.
- US GAAP Reconciliation: Be aware that IFRS net income ($5.0 billion) differs from US GAAP net income ($3.8 billion) due to purchase accounting adjustments, share-based compensation, and pension provisions.
- Share Repurchases: Verify the ongoing share buy-back program, with 24.3 million shares repurchased in 2003.